FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids
Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light. The approval of remestemcel-L (Ryoncil) specifies use in pediatric patients 2 months or older with steroid-refractory acute GVHD.
US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older
US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Silviu and the team at Mesoblast have opened a new chapter in harnessing MSC therapies to treat devastating conditions like SR-aGVHD. This approval validates the immense therapeutic promise of MSCs and inspires all of us working in this space to redouble our efforts to bring innovative solutions to patients in need.
US FDA approves Mesoblast's cell therapy for graft-versus-host disease
The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease (GVHD).
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...
MedPage Today on MSN2d
Next-Generation Therapies for Multiple Myeloma
The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients ...
Medscape2d
High-Dose Barbiturates for Refractory Intracranial Hypertension in Children With Severe Traumatic Brain Injury
Objectives: To evaluate high-dose barbiturates as a second-tier therapy for pediatric refractory intracranial hypertension complicating severe traumatic brain injury. Design: This is a ...
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
Medpage Today on MSN26d
TRK Inhibitor Active in Treatment-Refractory Glioblastoma
Used in conjunction with the oral sonosensitizing agent 5-ALA, the sonodynamic therapy led to a median OS of 15.7 months in ...
Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
Fast Track designation for NX-5948 is an important recognition of the unmet patient need in Waldenstrom’s macroglobulinemia, particularly in the growing number of patients whose cancer has progressed ...
Ottumwa Courier6h
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of ...
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis ...
oncnursingnews12d
Tafasitamab Shows Real-World Efficacy in Relapsed/Refractory DLBCL
Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective ...